Welcome to our dedicated page for Bristol-Myers Squibb news (Ticker: BMY), a resource for investors and traders seeking the latest updates and insights on Bristol-Myers Squibb stock.
Bristol Myers Squibb reports news on its pharmaceutical portfolio across oncology, cardiovascular disease and immunology, including regulatory decisions, clinical trial data, commercial access programs and product collaborations. Company updates include Sotyktu (deucravacitinib), a selective TYK2 inhibitor approved in the European Union for active psoriatic arthritis, and Eliquis (apixaban), an oral anticoagulant marketed through the Bristol Myers Squibb-Pfizer alliance.
Recurring developments also cover quarterly financial results, investor conference participation, debt and capital-market activity, research collaborations in cardiovascular and precision-medicine programs, and community initiatives tied to multiple myeloma care. The company’s news flow combines product-specific regulatory milestones with broader disclosures on operating performance and pipeline partnerships.
Bristol Myers Squibb (NYSE: BMY) announced the FDA's acceptance of its New Drug Application (NDA) for mavacamten, an oral allosteric modulator aimed at treating symptomatic obstructive hypertrophic cardiomyopathy (oHCM). The FDA set a PDUFA goal date for January 28, 2022. Clinical results from the Phase 3 EXPLORER-HCM trial indicated that mavacamten met primary and secondary endpoints, showcasing significant symptom relief and improved quality of life for patients. This first-in-class therapy addresses the underlying molecular defect of oHCM, a condition affecting approximately 160,000 to 200,000 people in the U.S. and EU.
Bristol Myers Squibb (NYSE:BMY) will release its first-quarter results on April 29, 2021, at 9 a.m. ET. Company executives will discuss financial performance and respond to investor inquiries during a conference call. Interested parties can access the live webcast at investor.bms.com or by dialing 800-458-4121 (U.S.) or +1 313-209-6672 (international) with confirmation code 3705525. A replay will be available from April 29 at 12:30 p.m. ET until May 13, 2021. For more information, visit BMS.com.
Bristol Myers Squibb (NYSE: BMY) will participate in a fireside chat at Barclays’ Virtual Global Healthcare Conference on March 9, 2021, at 3 p.m. ET. David Elkins, Executive Vice President and Chief Financial Officer, will address investor questions during the session. Investors and the public can access the live webcast at investor.bms.com, with materials available at the beginning of the event and an archived version posted later that day. The company focuses on developing innovative medicines for serious diseases.
Bristol Myers Squibb (NYSE: BMY) announced a quarterly dividend of $0.49 per share on its common stock, payable on May 3, 2021, to stockholders of record by April 1, 2021. Additionally, a dividend of $0.50 per share on its convertible preferred stock will be paid on June 1, 2021, to stockholders recorded by May 4, 2021. This reflects the company's commitment to returning value to shareholders while continuing to innovate in biopharmaceuticals.
Bristol Myers Squibb (NYSE: BMY) received a positive opinion from the European Medicines Agency's CHMP for the combination of Opdivo® (nivolumab) and Cabometyx® (cabozantinib) as a first-line treatment in adults with advanced renal cell carcinoma (RCC). This recommendation is based on the Phase 3 CheckMate -9ER trial, which showed significant improvement in progression-free survival and overall survival compared to sunitinib. The decision from the European Commission will follow this positive recommendation, marking a crucial step in enhancing treatment options for RCC patients.
Bristol Myers Squibb (NYSE: BMY) announced participation in the Cowen Virtual 41st Annual Health Care Conference on March 3, 2021, where Samit Hirawat, Chief Medical Officer, will present at 10:20 a.m. ET. The event will be webcast live for investors and the public, with an archived edition available later that day. For further information, materials will be accessible at investor.bms.com.
Bristol Myers Squibb (NYSE: BMY) has announced an $11 million donation to 56 nonprofit organizations to enhance health equity across the U.S. This funding is part of a larger $150 million commitment aimed at improving access to healthcare in underserved communities. The donation will support programs targeting various demographics, including racially and ethnically diverse populations. Bristol Myers Squibb plans to monitor the impact of these initiatives through regular evaluation reports. Additional investments of $50 million by 2025 will further these health equity efforts.
Bristol Myers Squibb (NYSE:BMY) has partnered with the American Music Therapy Association and Ben Platt to launch MS in Harmony, a digital platform designed for individuals with relapsing multiple sclerosis (RMS). This initiative aims to guide users towards achieving mind-body harmony through music therapy. Research indicates potential benefits of music therapy in alleviating both physical and mental symptoms of MS. The platform provides accessible resources, including video exercises led by certified music therapists, intended to support the MS community.
Bristol Myers Squibb (NYSE: BMY) will participate in a fireside chat at the Raymond James Virtual 42nd Annual Institutional Investors Conference on March 2, 2021, at 8:20 a.m. ET. David Elkins, CFO, will discuss the company's strategies and answer investor questions. The session will be broadcast live, and the public can access it via http://investor.bms.com. An archived version will also be available later that day. Bristol Myers Squibb is committed to delivering innovative medicines for serious diseases.
Bristol Myers Squibb (NYSE:BMY) announced a notice of redemption for its 4.000% Notes due 2023 and $42.25 million of its 3.250% Notes due 2023. The redemptions will occur on March 24, 2021, and March 9, 2021, respectively. The company plans to finance this through cash on hand, having already redeemed approximately $4.0 billion in debt related to its previously announced tender offers. This announcement serves solely as a notice of redemption and does not constitute an offer to sell or buy securities.